First-in-human study with CRISPR/Cas9-based gene editing in ATTR amyloid cardiomyopathy - PACE-CME

Firstinhuman study with CRISPRCasbased gene editing in ATTR amyloid cardiomyopathy

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Long-term efficacy and safety of intravenous iron in HF
Long-term efficacy and safety of intravenous iron in HF
AHA 2022
Long-term efficacy and safety of intravenous iron in HF
Low-dose statin lowers LDL-c more than dietary supplements
Low-dose statin lowers LDL-c more than dietary supplements
AHA 2022
Low-dose statin lowers LDL-c more than dietary supplements
- Luke J. Laffin, MD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
AHA 2022
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
- David Preiss, PhD
Is one diuretic better than the other diuretic in veterans with hypertension?
Is one diuretic better than the other diuretic in veterans with hypertension?
AHA 2022
Is one diuretic better than the other diuretic in veterans with hypertension?
- Areef Ishani, MD